Can Fite Biopharma Ltd
CANF0.673USD
-0.041-5.72%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
2.01BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Can Fite Biopharma Ltd Unternehmen
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Unternehmensinformationen
BörsenkürzelCANF
Name des UnternehmensCan Fite Biopharma Ltd
IPO-datumSep 22, 2005
Gegründet am1994
CEODr. Pnina Fishman, Ph.D.
Anzahl der mitarbeiter5
WertpapierartOrdinary Share
GeschäftsjahresendeSep 22
Addresse26 Ben Gurion Street
StadtRAMAT GAN
BörseTel Aviv Stock Exchange
LandIsrael
Postleitzahl5257346
Telefon97239241114
Websitehttps://www.canfite.com/
BörsenkürzelCANF
IPO-datumSep 22, 2005
Gegründet am1994
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Yaacov Goldman
Mr. Yaacov Goldman
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. Sari Fishman, Ph.D.
Dr. Sari Fishman, Ph.D.
Vice President - Business Development
Vice President - Business Development
--
--
Mr. Yoseph Borenstein
Mr. Yoseph Borenstein
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Yaacov Goldman
Mr. Yaacov Goldman
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 26
Aktualisiert: Sat, Jul 26
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Rhumbline Advisers Ltd. Partnership
0.29%
Abalone Asset Management Ltd.
0.18%
Morgan Stanley & Co. LLC
0.17%
BNP Paribas Securities Corp. North America
0.17%
XTX Markets LLC
0.11%
Other
99.08%
Aktionäre
Aktionäre
Anteil
Rhumbline Advisers Ltd. Partnership
0.29%
Abalone Asset Management Ltd.
0.18%
Morgan Stanley & Co. LLC
0.17%
BNP Paribas Securities Corp. North America
0.17%
XTX Markets LLC
0.11%
Other
99.08%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
0.58%
Research Firm
0.47%
Venture Capital
0.11%
Other
98.84%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
29
155.14K
1.17%
-710.53K
2025Q1
30
155.14K
1.17%
-710.63K
2024Q4
28
154.43K
1.51%
-671.86K
2024Q3
26
794.33K
11.46%
+115.72K
2024Q2
26
667.93K
11.77%
+152.94K
2024Q1
24
517.69K
9.97%
+253.94K
2023Q4
29
283.94K
5.78%
+189.77K
2023Q3
28
67.77K
1.66%
-429.92K
2023Q2
28
54.74K
1.34%
-433.22K
2023Q1
31
368.56K
9.03%
+211.26K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Rhumbline Advisers Ltd. Partnership
38.27K
0.29%
+11.39K
+42.37%
Mar 31, 2025
Abalone Asset Management Ltd.
23.81K
0.18%
-16.19K
-40.48%
Jun 30, 2024
Morgan Stanley & Co. LLC
23.21K
0.17%
-9.30K
-28.60%
Mar 31, 2025
BNP Paribas Securities Corp. North America
22.59K
0.17%
-2.60K
-10.32%
Mar 31, 2025
XTX Markets LLC
15.27K
0.12%
+15.27K
--
Mar 31, 2025
Virtu Americas LLC
13.74K
0.1%
+13.74K
--
Mar 31, 2025
CAPTRUST Financial Advisors
10.63K
0.08%
+10.63K
--
Mar 31, 2025
MainStreet Advisors
3.00K
0.02%
--
--
Mar 31, 2025
Wells Fargo Advisors
2.70K
0.02%
+200.00
+8.00%
Mar 31, 2025
Costello Asset Management, Inc.
1.00K
0.01%
+1.00K
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Jan 03, 2023
Merger
10<1
Jan 03, 2023
Merger
10<1
Jan 03, 2023
Merger
10<1
Jan 03, 2023
Merger
10<1
Datum
Art
Verhältnis
Jan 03, 2023
Merger
10<1
Jan 03, 2023
Merger
10<1
Jan 03, 2023
Merger
10<1
Jan 03, 2023
Merger
10<1
